About   Help   FAQ
Phenotypes associated with this allele
Allele Symbol
Allele Name
Allele ID
Tg(Scgb1a1-rtTA)1Jaw
transgene insertion 1, Jeffrey A Whitsett
MGI:2445707
Summary 21 genotypes
Jump to Allelic Composition Genetic Background Genotype ID
cn1
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(Scgb1a1-rtTA)1Jaw/0
involves: 129S4/SvJae MGI:4368025
cn2
Col1a1tm5(tetO-GFP/RNAi:Cdkn2a)Slowe/Col1a1+
Gt(ROSA)26Sortm1(Luc)Kael/Gt(ROSA)26Sortm1(rtTA*M2)Jae
Krastm4Tyj/Kras+
Tg(Scgb1a1-rtTA)1Jaw/0
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6 MGI:4999988
cn3
Foxa2tm1Khk/Foxa2tm1Khk
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-cre)1Jaw/0
Not Specified MGI:3036450
cx4
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-MYC)36Bop/0
involves: 129 * C57BL/6 MGI:4946282
cx5
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-Aimp1)29872Mcla/0
involves: 129 * C57BL/6 MGI:5604244
cx6
Col1a1tm1(tetO-EML4/ALK)Kkw/Col1a1+
Tg(Scgb1a1-rtTA)1Jaw/0
involves: 129 * C57BL/6 MGI:5527337
cx7
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-IL1B)KBry/0
involves: 129 * C57BL/6 MGI:5444503
cx8
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-CTGF)#Swu/0
involves: 129 * C57BL/6 * C57BL/6J MGI:5473719
cx9
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-EGFR*L858R)#Hev/0
involves: 129 * C57BL/6 * CBA MGI:5634289
cx10
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-EGFR*T790M*L858R)19Kkw/0
involves: 129 * C57BL/6 * FVB/N MGI:5781131
cx11
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-PIK3CA*H1047R)13Lca/0
involves: 129 * C57BL/6 * FVB/N MGI:3834442
cx12
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-Spdef)1Jaw/0
involves: 129 * C57BL/6 * FVB/N MGI:4410330
cx13
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-PTPN11*E76K)#Jiwu/0
involves: 129 * C57BL/6 * FVB/N MGI:5688300
cx14
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-EGFR*T790M)8Paow/0
involves: 129 * C57BL/6 * FVB/N MGI:5705252
cx15
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-EGFR*T790M*L858R)51Paow/0
involves: 129 * C57BL/6 * FVB/N MGI:5705253
cx16
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-EGFR*L858R)56Hev/0
involves: C57BL/6 * CBA MGI:3690087
cx17
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-EGFR*delta19)11Hev/0
involves: C57BL/6 * CBA MGI:3690458
cx18
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-EGFR*L858R)57Hev/0
involves: C57BL/6 * CBA MGI:3690090
cx19
Tg(tetO-Plau)1Ths/0
Tg(Scgb1a1-rtTA)1Jaw/0
involves: C57BL/6 * SJL MGI:2652187
cx20
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO/CMV-KRAS*G12C)9.1Msmi/0
involves: FVB/N MGI:3693292
cx21
Tg(tetO-Vegfa)90Ala/?
Tg(Scgb1a1-rtTA)1Jaw/?
involves: FVB/N MGI:3586366


Genotype
MGI:4368025
cn1
Allelic
Composition
Krastm4Tyj/Kras+
Trp53tm1Brn/Trp53tm1Brn
Tg(Scgb1a1-rtTA)1Jaw/0
Genetic
Background
involves: 129S4/SvJae
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Krastm4Tyj mutation (4 available); any Kras mutation (32 available)
Tg(Scgb1a1-rtTA)1Jaw mutation (3 available)
Trp53tm1Brn mutation (6 available); any Trp53 mutation (145 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
neoplasm
• infiltrating inflammatory cells recruited to tumors in which NF-kB has been inhibited
• tumorigenesis is initiated by infection with lentiviruses expressing Cre and Nfkbia lentiviruses
• doxycycline (Dox)-mediated induction of Nfkbia expression specifically in the tumor cells starting at 16 weeks after tumor initiation results in a significantly diminished tumour growth rate
• tumorigenesis is initiated by infection with lentiviruses expressing Cre and Nfkbia lentiviruses
• doxycycline (Dox)-mediated induction of Nfkbia expression specifically in the tumor cells leads to a significant impairment of tumour development
• tumorigenesis is initiated by infection with lentiviruses expressing Cre and Nfkbia lentiviruses




Genotype
MGI:4999988
cn2
Allelic
Composition
Col1a1tm5(tetO-GFP/RNAi:Cdkn2a)Slowe/Col1a1+
Gt(ROSA)26Sortm1(Luc)Kael/Gt(ROSA)26Sortm1(rtTA*M2)Jae
Krastm4Tyj/Kras+
Tg(Scgb1a1-rtTA)1Jaw/0
Genetic
Background
involves: 129S4/SvJae * 129S6/SvEvTac * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm5(tetO-GFP/RNAi:Cdkn2a)Slowe mutation (0 available); any Col1a1 mutation (90 available)
Gt(ROSA)26Sortm1(Luc)Kael mutation (2 available); any Gt(ROSA)26Sor mutation (329 available)
Gt(ROSA)26Sortm1(rtTA*M2)Jae mutation (13 available); any Gt(ROSA)26Sor mutation (329 available)
Krastm4Tyj mutation (4 available); any Kras mutation (32 available)
Tg(Scgb1a1-rtTA)1Jaw mutation (3 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• mice treated with a cre-expressing adenovirus and treated with doxycycline exhibit reduced survival compared with control mice

neoplasm
• mice treated with a cre-expressing adenovirus and treated with doxycycline exhibit increased tumor incidence (size and number) in the lungs with rare noninvasive lung adenomas compared with control mice
• however, mice treated with a cre-expressing adenovirus and treated with doxycycline exhibit tumor regression after doxycycline removal
• in mice treated with a cre-expressing adenovirus and treated with doxycycline

respiratory system
• in mice treated with a cre-expressing adenovirus and treated with doxycycline
• rapid shallow breathing in mice treated with a cre-expressing adenovirus and treated with doxycycline

growth/size/body
• in mice treated with a cre-expressing adenovirus and treated with doxycycline




Genotype
MGI:3036450
cn3
Allelic
Composition
Foxa2tm1Khk/Foxa2tm1Khk
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-cre)1Jaw/0
Genetic
Background
Not Specified
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Foxa2tm1Khk mutation (1 available); any Foxa2 mutation (16 available)
Tg(Scgb1a1-rtTA)1Jaw mutation (3 available)
Tg(tetO-cre)1Jaw mutation (4 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
N
• no increase in the number of neutrophils or macrophages in mice treated with doxycycline from E0 through P16

respiratory system
• goblet cell hyperplasia, associated with the accumulation of both neutral and acidic mucins, in the larger airways of mice treated with doxycycline from E0 through P16
• neither airspace nor alveolar morphological abnormalities were detected
• increased in mice treated with doxycycline
• decreased in mice treated with doxycycline




Genotype
MGI:4946282
cx4
Allelic
Composition
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-MYC)36Bop/0
Genetic
Background
involves: 129 * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Scgb1a1-rtTA)1Jaw mutation (3 available)
Tg(tetO-MYC)36Bop mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
respiratory system
• 100% of tumors show activating Kras mutations
• mice treated with DOX develop papillary adenomas
• 23.8% penetrance of adenocarcionomas in untreated mice and 56.7% penetrance in DOX treated mice

mortality/aging
• mice fed a diet supplemented with DOX to stimulate transactivating function of the rtTA protein and induce MYC expression exhibit reduced lifespan

neoplasm
• 16.7% of DOX treated mice exhibit metastases
• 100% of tumors show activating Kras mutations
• mice treated with DOX develop papillary adenomas
• 23.8% penetrance of adenocarcionomas in untreated mice and 56.7% penetrance in DOX treated mice




Genotype
MGI:5604244
cx5
Allelic
Composition
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-Aimp1)29872Mcla/0
Genetic
Background
involves: 129 * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Scgb1a1-rtTA)1Jaw mutation (3 available)
Tg(tetO-Aimp1)29872Mcla mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
cellular
• 3 fold increase in caspase 3 activity in lung alveolar cells is measured as early as 4 weeks after doxycycline (dox) induction

hematopoietic system
• 28 weeks of doxycycline induction results in an increase in the number of alveolar macrophages in bronchoalveolar lavage fluid (BALF) and lung parenchyma from lung lysates

immune system
• 28 weeks of doxycycline induction results in an increase in the number of alveolar macrophages in bronchoalveolar lavage fluid (BALF) and lung parenchyma from lung lysates

respiratory system
• 3 fold increase in caspase 3 activity in lung alveolar cells is measured as early as 4 weeks after doxycycline (dox) induction
• increase in diameters of acinar airspaces (comprising alveolar ducts and alveoli) following dox treatment as compared to controls
• following doxycycline induction
• following doxycycline induction
• following doxycycline induction




Genotype
MGI:5527337
cx6
Allelic
Composition
Col1a1tm1(tetO-EML4/ALK)Kkw/Col1a1+
Tg(Scgb1a1-rtTA)1Jaw/0
Genetic
Background
involves: 129 * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Col1a1tm1(tetO-EML4/ALK)Kkw mutation (0 available); any Col1a1 mutation (90 available)
Tg(Scgb1a1-rtTA)1Jaw mutation (3 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• doxycycline-treated mice exhibit a median survival of 7 to 8 weeks

neoplasm
• withdrawal of doxycycline leads to complete tumor regression
• ALK kinase inhibitor is a more effective therapy than chemotherapy in doxycycline-treated mice
• doxycycline-treated mice develop lung tumorigenesis with a latency of less than 10 days
• however, withdrawal of doxycycline leads to complete tumor regression
• adenocarcinomas predominantly bronchioloalveolar carcinoma with occasional pleural space and airway invasion by an acinar component in doxycycline-treated mice

growth/size/body
• in tumor-bearing, doxycycline-treated mice in the first 4 weeks

respiratory system
N
• untreated mice exhibit normal lung histology
• doxycycline-treated mice develop lung tumorigenesis with a latency of less than 10 days
• however, withdrawal of doxycycline leads to complete tumor regression
• adenocarcinomas predominantly bronchioloalveolar carcinoma with occasional pleural space and airway invasion by an acinar component in doxycycline-treated mice

Mouse Models of Human Disease
OMIM ID Ref(s)
Lung Cancer 211980 J:166724




Genotype
MGI:5444503
cx7
Allelic
Composition
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-IL1B)KBry/0
Genetic
Background
involves: 129 * C57BL/6
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Scgb1a1-rtTA)1Jaw mutation (3 available)
Tg(tetO-IL1B)KBry mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• about 50% of newborns from females provided with doxycycline during pregnancy and lactation die before 7 days of age

growth/size/body
• pups from females provided with doxycycline during pregnancy and lactation weight about 36% less than controls
• postnatal growth of newborns from females provided with doxycycline during pregnancy and lactation is decreased

respiratory system
• pups from females provided with doxycycline during pregnancy and lactation exhibit abnormal vascular development of the lungs, showing capillaries of varying sizes scattered within the thick septa at P3 compared to control lungs that show capillaries lining the alveolar septa, and by P14, capillaries are dysmorphic
• mutants administered doxycycline for 8 days show a 6- to 12-fold increase in the total number of inflammatory cells in bronchoalveolar lavage fluid, mainly due to an influx of neutrophils into the lung; most of the remaining cells are macrophages (J:107601)
• an increase in inflammatory cells is seen in the alveoli and parenchyma of lungs in mutants administered doxycycline for 5 weeks (J:107601)
• however, lung histology is normal in mutants not given doxycycline (J:107601)
• fetal and neonatal lungs in mutants from females provided with doxycycline during pregnancy and lactation exhibit neutrophil and macrophage infiltration in airways and airspaces (J:130523)
• number of neutrophils in the lungs increases rapidly from E18.5 to P0 and remains stable after that time, however the number of macrophages continues to increase during the first week of life (J:130523)
• newborns from females provided with doxycycline during pregnancy and lactation exhibit disrupted alveolar development, with absence of septation and thus thicker septa of distal airspaces and an increase in alveolar chord length compared to controls
• pups from females provided with doxycycline during pregnancy and lactation exhibit thickened epithelium and subepithelial smooth muscle in airway walls, indicating airway remodeling
• mean alveolar cord length is larger in mutants administered doxycycline for 5 weeks compared to controls
• airway mucus metaplasia in mutants administered doxycycline for 5 weeks
• newborns from females provided with doxycycline during pregnancy and lactation exhibit increased thickness of saccular/alveolar walls by 23% on P0 and by 38% on P7
• severe distal airspace enlargement is seen in mutants administered doxycycline for 5 weeks
• newborns from females provided with doxycycline during pregnancy and lactation exhibit thicker septa of distal airspaces
• mutants administered doxycycline for 5 weeks exhibit distal airspace enlargement consistent with emphysema
• elastin fibers are disrupted, frayed and short in the lungs of mutants administered doxycycline for 5 weeks compared to controls, indicating elastin degradation (J:107601)
• newborns from females provided with doxycycline during pregnancy and lactation exhibit abnormal elastin structure in the distal lung at P7, with poorly organized elastin fibers in the walls of airspaces and lack of elastin in septal crests, and by 3 weeks of age, elastin fibers are splayed and disorganized and are often perpendicular to the airspace wall, have inflammatory cells infiltrating the bundles, and distribution in the blunted secondary crests is abnormal (J:130523)
• bronchiolar thickening and peribronchiolar lymphocytic nodules are seen in mutants administered doxycycline for 5 weeks
• lung fibrosis with extensive subepithelial fibrosis is seen in mutants administered doxycycline for 5 weeks, with lesions showing increased collagen deposition
• pups from females provided with doxycycline during pregnancy and lactation exhibit goblet cell hyperplasia
• lung volumes and lung volume/body weight ratios are increased after 5 weeks of doxycycline administration
• newborns from females provided with doxycycline during pregnancy and lactation (fetuses receive doxycycline transplacentally and newborns receive it from the mother's milk) develop respiratory insufficiency within several days after birth

immune system
• mutants administered doxycycline for 5 weeks exhibit increased production of CXC chemokines Cxcl1 (KC) and Cxcl2 (MIP-2) (J:107601)
• fetal and neonatal lungs in mutants from females provided with doxycycline during pregnancy and lactation exhibit increased production of chemokines, KC, MIP-2, MCP-1 and MCP-2 (J:130523)
• mutants administered doxycycline for 8 days show a 6- to 12-fold increase in the total number of inflammatory cells in bronchoalveolar lavage fluid, mainly due to an influx of neutrophils into the lung; most of the remaining cells are macrophages (J:107601)
• an increase in inflammatory cells is seen in the alveoli and parenchyma of lungs in mutants administered doxycycline for 5 weeks (J:107601)
• however, lung histology is normal in mutants not given doxycycline (J:107601)
• fetal and neonatal lungs in mutants from females provided with doxycycline during pregnancy and lactation exhibit neutrophil and macrophage infiltration in airways and airspaces (J:130523)
• number of neutrophils in the lungs increases rapidly from E18.5 to P0 and remains stable after that time, however the number of macrophages continues to increase during the first week of life (J:130523)

homeostasis/metabolism
• mutants administered doxycycline for 5 weeks exhibit increased production of CXC chemokines Cxcl1 (KC) and Cxcl2 (MIP-2) (J:107601)
• fetal and neonatal lungs in mutants from females provided with doxycycline during pregnancy and lactation exhibit increased production of chemokines, KC, MIP-2, MCP-1 and MCP-2 (J:130523)

cardiovascular system
• pups from females provided with doxycycline during pregnancy and lactation exhibit abnormal vascular development of the lungs, showing capillaries of varying sizes scattered within the thick septa at P3 compared to control lungs that show capillaries lining the alveolar septa, and by P14, capillaries are dysmorphic




Genotype
MGI:5473719
cx8
Allelic
Composition
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-CTGF)#Swu/0
Genetic
Background
involves: 129 * C57BL/6 * C57BL/6J
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Scgb1a1-rtTA)1Jaw mutation (3 available)
Tg(tetO-CTGF)#Swu mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
respiratory system
• pups nursing on dams administered doxycycline from P1 to P14 exhibit decreased capillary formation in alveolar septa
• pups nursing on dams administered doxycycline from P1 to P14 exhibit disrupted alveolarization, showing a 27% and 31% decrease in the mean alveolar airspace area and mean cord length, respectively
• pups nursing on dams administered doxycycline from P1 to P14 exhibit disorganized elastic fiber deposition on alveolar surfaces and in septa
• pups nursing on dams administered doxycycline from P1 to P14 exhibit a 34% decrease in secondary septa
• marker analysis indicates that pups nursing on dams administered doxycycline from P1 to P14 exhibit increased myofibroblast differentiation in alveolar septa
• pups nursing on dams administered doxycycline from P1 to P14 exhibit a 48% increase in the proliferating cell index in alveolar septa
• pups nursing on dams administered doxycycline from P1 to P14 exhibit decreased capillary formation in alveolar septa
• pups nursing on dams administered doxycycline from P1 to P14 exhibit thickening in the peribronchial/peribronchiolar and perivascular regions of the lungs and increased collagen deposition in these regions, indicating fibrosis

cardiovascular system
• pups nursing on dams administered doxycycline from P1 to P14 exhibit decreased capillary formation in alveolar septa




Genotype
MGI:5634289
cx9
Allelic
Composition
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-EGFR*L858R)#Hev/0
Genetic
Background
involves: 129 * C57BL/6 * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Scgb1a1-rtTA)1Jaw mutation (3 available)
Tg(tetO-EGFR*L858R)#Hev mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
respiratory system
• tumor bearing mice treated with the geldanamycin analogue, 17-AAG, which inhibits Hsp90, show a transient degeneration of tumors (J:128700)
• mice treated with doxycycline develop lung adenocarcinomas (J:213447)
• mice treated with doxycycline, followed by treatment with a tyrosine kinase inhibitor erlotinib, initially show tumor regression but eventually develop tumors resistant to long-term erlotinib treatment (J:213447)
• treatment of doxycycline treated mice that have erlotinib-resistant tumors with a MEK inhibitor, trametinib, results in tumor regression (J:213447)
• treatment of doxycline treated mice with trametinib alone does not have an effect on tumor growth (J:213447)

neoplasm
• tumor bearing mice treated with the geldanamycin analogue, 17-AAG, which inhibits Hsp90, show a transient degeneration of tumors (J:128700)
• mice treated with doxycycline develop lung adenocarcinomas (J:213447)
• mice treated with doxycycline, followed by treatment with a tyrosine kinase inhibitor erlotinib, initially show tumor regression but eventually develop tumors resistant to long-term erlotinib treatment (J:213447)
• treatment of doxycycline treated mice that have erlotinib-resistant tumors with a MEK inhibitor, trametinib, results in tumor regression (J:213447)
• treatment of doxycline treated mice with trametinib alone does not have an effect on tumor growth (J:213447)

Mouse Models of Human Disease
OMIM ID Ref(s)
Lung Cancer 211980 J:128700 , J:213447




Genotype
MGI:5781131
cx10
Allelic
Composition
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-EGFR*T790M*L858R)19Kkw/0
Genetic
Background
involves: 129 * C57BL/6 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Scgb1a1-rtTA)1Jaw mutation (3 available)
Tg(tetO-EGFR*T790M*L858R)19Kkw mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
immune system
• doxycycline treated mice often exhibit focal pneumonia with increased number of intra-alveolar macrophages filling the alveolar spaces, most likely due to airway obstruction by bronchial tumors

neoplasm
• metastatic foci of adenocarcinomas are occasionally seen in lymph nodes of doxycycline treated mice
• mice develop lung tumors after 5-6 weeks of doxycycline administration
• early lesions develop in alveoli after 2-3 weeks of doxycycline administration
• withdrawal of doxycycline results in decreased proliferation and increased apoptosis of cancer cells and complete tumor regression by 10 days of withdrawal
• typical bronchioloalveolar carcinoma is seen after 4-5 weeks of doxycycline administration
• invasive peripheral adenocarcinomas with bronchioloalveolar features appears after 7-9 weeks of doxycycline administration and is the dominant histological pattern after 12 weeks of treatment
• early papillary neoplasia in the bronchioles are seen after 2-3 weeks of doxycycline administration which progress into bronchial papillary adenocarcinomas after an additional 6-8 weeks of doxycycline treatment
• both types of lung adenocarcinomas that develop in doxycycline administered mice are resistant to erlotinib treatment
• bronchial tumors that develop in doxycycline administered mice are not sensitive to HKI-272 treatment while peripheral adenocarcinomas show some sensitivity to this treatment
• bronchial and peripheral tumors that develop in doxycycline administered mice are sensitive to combination therapy with HKI-272 and rapamycin

respiratory system
• doxycycline treated mice often exhibit focal pneumonia with increased number of intra-alveolar macrophages filling the alveolar spaces, most likely due to airway obstruction by bronchial tumors
• mice develop lung tumors after 5-6 weeks of doxycycline administration
• early lesions develop in alveoli after 2-3 weeks of doxycycline administration
• withdrawal of doxycycline results in decreased proliferation and increased apoptosis of cancer cells and complete tumor regression by 10 days of withdrawal
• typical bronchioloalveolar carcinoma is seen after 4-5 weeks of doxycycline administration
• invasive peripheral adenocarcinomas with bronchioloalveolar features appears after 7-9 weeks of doxycycline administration and is the dominant histological pattern after 12 weeks of treatment
• early papillary neoplasia in the bronchioles are seen after 2-3 weeks of doxycycline administration which progress into bronchial papillary adenocarcinomas after an additional 6-8 weeks of doxycycline treatment
• both types of lung adenocarcinomas that develop in doxycycline administered mice are resistant to erlotinib treatment
• bronchial tumors that develop in doxycycline administered mice are not sensitive to HKI-272 treatment while peripheral adenocarcinomas show some sensitivity to this treatment
• bronchial and peripheral tumors that develop in doxycycline administered mice are sensitive to combination therapy with HKI-272 and rapamycin

Mouse Models of Human Disease
OMIM ID Ref(s)
Lung Cancer 211980 J:122849




Genotype
MGI:3834442
cx11
Allelic
Composition
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-PIK3CA*H1047R)13Lca/0
Genetic
Background
involves: 129 * C57BL/6 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Scgb1a1-rtTA)1Jaw mutation (3 available)
Tg(tetO-PIK3CA*H1047R)13Lca mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
respiratory system
• at 12 weeks following doxycycline treatment, mice develop lung adenocarcinomas
• however, withdrawal of doxycycline or treatment with NVP-BEZ235 leads to tumor regression

neoplasm
• at 12 weeks following doxycycline treatment, mice develop lung adenocarcinomas
• however, withdrawal of doxycycline or treatment with NVP-BEZ235 leads to tumor regression

Mouse Models of Human Disease
OMIM ID Ref(s)
Lung Cancer 211980 J:142254




Genotype
MGI:4410330
cx12
Allelic
Composition
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-Spdef)1Jaw/0
Genetic
Background
involves: 129 * C57BL/6 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Scgb1a1-rtTA)1Jaw mutation (3 available)
Tg(tetO-Spdef)1Jaw mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
respiratory system
• doxycycline-treated mice exhibit goblet cell differentiation without proliferation unlike similarly treated wild-type mice
• doxycycline-treated mice exhibit hyperplasia of lung goblet cells compared with similarly treated wild-type mice




Genotype
MGI:5688300
cx13
Allelic
Composition
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-PTPN11*E76K)#Jiwu/0
Genetic
Background
involves: 129 * C57BL/6 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Scgb1a1-rtTA)1Jaw mutation (3 available)
Tg(tetO-PTPN11*E76K)#Jiwu mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
respiratory system
• atypical adenomatous hyperplasia is seen in mice induced with doxycycline (Dox) for 6 months
• 3 of 12 mice induced with Dox for 6 months develop small lung adenomas
• 13 of 15 mice induced with Dox for 9 months develop lung tumors; tumors at 9 months of Dox induction are larger in size and some progress to adenocarcinoma
• lung tumors regress after Dox withdrawal
• lung tumors in Dox treated mice are papillary or mixed subtypes of adenomas and progress to mixed subtypes and solid adenocarcinomas and resemble non-small cell lung cancer

neoplasm
• atypical adenomatous hyperplasia is seen in mice induced with doxycycline (Dox) for 6 months
• 3 of 12 mice induced with Dox for 6 months develop small lung adenomas
• 13 of 15 mice induced with Dox for 9 months develop lung tumors; tumors at 9 months of Dox induction are larger in size and some progress to adenocarcinoma
• lung tumors regress after Dox withdrawal
• lung tumors in Dox treated mice are papillary or mixed subtypes of adenomas and progress to mixed subtypes and solid adenocarcinomas and resemble non-small cell lung cancer

Mouse Models of Human Disease
OMIM ID Ref(s)
Lung Cancer 211980 J:212505




Genotype
MGI:5705252
cx14
Allelic
Composition
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-EGFR*T790M)8Paow/0
Genetic
Background
involves: 129 * C57BL/6 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Scgb1a1-rtTA)1Jaw mutation (3 available)
Tg(tetO-EGFR*T790M)8Paow mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
respiratory system
• most mice develop lung lesions only after long-term (28-32 weeks) administration of doxycycline (dox)
• lung tumors of dox treated mice are invasive lung adenocarcinomas
• regression of tumors is seen after removal of the inducer dox
• lung tumors of dox treated mice are resistant to treatment with erlotinib

neoplasm
• most mice develop lung lesions only after long-term (28-32 weeks) administration of doxycycline (dox)
• lung tumors of dox treated mice are invasive lung adenocarcinomas
• regression of tumors is seen after removal of the inducer dox
• lung tumors of dox treated mice are resistant to treatment with erlotinib

Mouse Models of Human Disease
OMIM ID Ref(s)
Lung Cancer 211980 J:128700




Genotype
MGI:5705253
cx15
Allelic
Composition
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-EGFR*T790M*L858R)51Paow/0
Genetic
Background
involves: 129 * C57BL/6 * FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Scgb1a1-rtTA)1Jaw mutation (3 available)
Tg(tetO-EGFR*T790M*L858R)51Paow mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
respiratory system
• mice on a dox diet for 17.5 weeks of age develop a large lung tumor burden; these are heterogeneous adenocarcinomas involving the solid, bronchioalveolar, and papillary subtypes
• tumors of dox treated mice are negative for CC26, a Clara cell protein, and positive for surfactant protein-C, a type II pneumocyte marker, indicating a type II cell-like phenotype
• regression of tumors is seen as early as one week after removal of the inducer dox, however microscopic islands of tumor cells can still be seen even after mice are off dox for 4 weeks
• lung tumors of dox treated mice are resistant to treatment with erlotinib
• tumor bearing mice treated with the geldanamycin analogue, 17-AAG, which inhibits Hsp90, show tumor necrosis although viable tumor nodules remain
• however, mice maintained without dox exhibit normal lung morphology
• mice on a doxycycline (dox)-containing diet for 17.5 weeks become tachypneic

neoplasm
• mice on a dox diet for 17.5 weeks of age develop a large lung tumor burden; these are heterogeneous adenocarcinomas involving the solid, bronchioalveolar, and papillary subtypes
• tumors of dox treated mice are negative for CC26, a Clara cell protein, and positive for surfactant protein-C, a type II pneumocyte marker, indicating a type II cell-like phenotype
• regression of tumors is seen as early as one week after removal of the inducer dox, however microscopic islands of tumor cells can still be seen even after mice are off dox for 4 weeks
• lung tumors of dox treated mice are resistant to treatment with erlotinib
• tumor bearing mice treated with the geldanamycin analogue, 17-AAG, which inhibits Hsp90, show tumor necrosis although viable tumor nodules remain
• however, mice maintained without dox exhibit normal lung morphology

Mouse Models of Human Disease
OMIM ID Ref(s)
Lung Cancer 211980 J:128700




Genotype
MGI:3690087
cx16
Allelic
Composition
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-EGFR*L858R)56Hev/0
Genetic
Background
involves: C57BL/6 * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Scgb1a1-rtTA)1Jaw mutation (3 available)
Tg(tetO-EGFR*L858R)56Hev mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
respiratory system
• as early as 2 weeks after initiation of doxycycline, lungs of bitransgenic mice exhibit scattered thickening of the alveolar walls due to proliferation of abnormal pneumocytes, with a lepidic growth pattern similar to human bronchioalveolar carcinoma (BAC), a subtype of lung adenocarcinoma; this wall thickening may be progressive, gradually compressing the air spaces
• after longer than 4 weeks on doxycycline, bitransgenic mice develop multifocal invasive adenocarcinoma of the lungs, with papilliform tumors of varying size embedded in the abnormal lung parenchyma; the adenocarcinoma cells have moderately pleomorphic nuclei with large nucleoli
• immunohistochemical analysis demonstrates that the tumors in these mice express the mutant human EGFR protein and that they are composed of cells that express surfactant protein C, characteristic of type II pneumocytes, but not Clara cell protein CC26
• discontinuation of doxycycline treatment in two mice after 122 and 180 days resulted in diminution of lung opacities on MRI at 9 and 2 days afterward; histologic examination of the second mouse immediately after MRI found tumors present, whereas examination of the first mouse 31 days after deinduction revealed that the tumors had regressed completely, leaving scar tissue
• treatment of tumor-bearing mice with the tyrosine kinase inhibitor erlotinib, while the mice continued receiving doxycycline, resulted in partial to complete disappearance of opacities on MRI in all mice on at least 12.5 mg kg-1 d-1 erlotinib and, in mice examined after at least 4 days on erlotinib, complete or nearly complete (i.e., some residual tumor cells remained) histological regression of the tumors
• after only 4 days' induction with doxycycline, lung tissue from doubly transgenic mice contained nearly 2-fold the number of type II pneumocytes, identified by staining with antibody against surfactant protein C, than control tissue
• immunohistochemical analysis demonstrates that the tumors induced by doxycycline in these mice express the mutant human EGFR protein and that they are composed of cells that express surfactant protein C, characteristic of type II pneumocytes, but not Clara cell protein CC26
• as early as 2 weeks after initiation of doxycycline, lungs of bitransgenic mice exhibit scattered thickening of the alveolar walls due to proliferation of abnormal pneumocytes, with a lepidic growth pattern similar to human bronchioalveolar carcinoma (BAC), a subtype of lung adenocarcinoma; this wall thickening may be progressive, gradually compressing the air spaces

neoplasm
• as early as 2 weeks after initiation of doxycycline, lungs of bitransgenic mice exhibit scattered thickening of the alveolar walls due to proliferation of abnormal pneumocytes, with a lepidic growth pattern similar to human bronchioalveolar carcinoma (BAC), a subtype of lung adenocarcinoma; this wall thickening may be progressive, gradually compressing the air spaces
• after longer than 4 weeks on doxycycline, bitransgenic mice develop multifocal invasive adenocarcinoma of the lungs, with papilliform tumors of varying size embedded in the abnormal lung parenchyma; the adenocarcinoma cells have moderately pleomorphic nuclei with large nucleoli
• immunohistochemical analysis demonstrates that the tumors in these mice express the mutant human EGFR protein and that they are composed of cells that express surfactant protein C, characteristic of type II pneumocytes, but not Clara cell protein CC26
• discontinuation of doxycycline treatment in two mice after 122 and 180 days resulted in diminution of lung opacities on MRI at 9 and 2 days afterward; histologic examination of the second mouse immediately after MRI found tumors present, whereas examination of the first mouse 31 days after deinduction revealed that the tumors had regressed completely, leaving scar tissue
• treatment of tumor-bearing mice with the tyrosine kinase inhibitor erlotinib, while the mice continued receiving doxycycline, resulted in partial to complete disappearance of opacities on MRI in all mice on at least 12.5 mg kg-1 d-1 erlotinib and, in mice examined after at least 4 days on erlotinib, complete or nearly complete (i.e., some residual tumor cells remained) histological regression of the tumors

Mouse Models of Human Disease
OMIM ID Ref(s)
Lung Cancer 211980 J:109092




Genotype
MGI:3690458
cx17
Allelic
Composition
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-EGFR*delta19)11Hev/0
Genetic
Background
involves: C57BL/6 * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Scgb1a1-rtTA)1Jaw mutation (3 available)
Tg(tetO-EGFR*delta19)11Hev mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
respiratory system
• a bitransgenic mouse examined after 13 days on doxycycline exhibited scattered thickening of the alveolar walls due to proliferation of abnormal pneumocytes, with a lepidic growth pattern similar to human bronchioalveolar carcinoma (BAC); animals examined after 28 days or longer on doxycycline exhibited BAC-like lesions at the lung periphery
• mice on doxycycline 28 days or longer exhibit multifocal, frondiform tumors radiating from bronchioalveolar duct junctions (BADJ) into the surrounding, BAC-free parenchyma; more advanced tumors form compact papilliform masses
• discontinuation of doxycycline treatment in two mice after 99 and 168 days resulted in partial remission of lung opacities on MRI at 6 and 4 days, respectively; histologic examination 4 days after deinduction found tumors still present, but at 31 days revealed that the tumors had regressed completely, leaving scar tissue
• treatment of two tumor-bearing bitransgenic mice (the second heterozygous for a Trp53-inactivating mutation) with the tyrosine kinase inhibitor erlotinib, while the mice continued receiving doxycycline, resulted in partial disappearance of opacities on MRI at 4 and 14 days and, after 4 days and 4 weeks on erlotinib, respectively, nearly complete histological regression of the tumors (i.e., some residual tumor cells remained)
• a bitransgenic mouse examined histologically 8 days after initiation of doxycycline exhibited proliferative lung lesions characteristic of early atypical adenomatous hyperplasia (AHH) at the lung periphery
• immunohistochemical analysis demonstrates that the tumors induced in these mice express the mutant human EGFR protein and that they are composed of cells that express surfactant protein C, characteristic of type II pneumocytes, but not Clara cell protein CC26
• bitransgenic mice on doxycycline 28 days or longer exhibit multifocal, frondiform tumors arising and radiating from bronchioalveolar duct junctions (BADJ) into the surrounding, BAC-free parenchyma; more advanced tumors form compact papilliform masses

neoplasm
• a bitransgenic mouse examined after 13 days on doxycycline exhibited scattered thickening of the alveolar walls due to proliferation of abnormal pneumocytes, with a lepidic growth pattern similar to human bronchioalveolar carcinoma (BAC); animals examined after 28 days or longer on doxycycline exhibited BAC-like lesions at the lung periphery
• mice on doxycycline 28 days or longer exhibit multifocal, frondiform tumors radiating from bronchioalveolar duct junctions (BADJ) into the surrounding, BAC-free parenchyma; more advanced tumors form compact papilliform masses
• discontinuation of doxycycline treatment in two mice after 99 and 168 days resulted in partial remission of lung opacities on MRI at 6 and 4 days, respectively; histologic examination 4 days after deinduction found tumors still present, but at 31 days revealed that the tumors had regressed completely, leaving scar tissue
• treatment of two tumor-bearing bitransgenic mice (the second heterozygous for a Trp53-inactivating mutation) with the tyrosine kinase inhibitor erlotinib, while the mice continued receiving doxycycline, resulted in partial disappearance of opacities on MRI at 4 and 14 days and, after 4 days and 4 weeks on erlotinib, respectively, nearly complete histological regression of the tumors (i.e., some residual tumor cells remained)

Mouse Models of Human Disease
OMIM ID Ref(s)
Lung Cancer 211980 J:109092




Genotype
MGI:3690090
cx18
Allelic
Composition
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO-EGFR*L858R)57Hev/0
Genetic
Background
involves: C57BL/6 * CBA
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Scgb1a1-rtTA)1Jaw mutation (3 available)
Tg(tetO-EGFR*L858R)57Hev mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
respiratory system
• as early as 2 weeks after initiation of doxycycline, lungs of bitransgenic mice exhibit scattered thickening of the alveolar walls due to proliferation of abnormal pneumocytes, with a lepidic growth pattern similar to human bronchioalveolar carcinoma (BAC), a subtype of lung adenocarcinoma; this wall thickening may be progressive, gradually compressing the air spaces
• after longer than 4 weeks on doxycycline, bitransgenic mice develop multifocal invasive adenocarcinoma of the lungs, with papilliform tumors of varying size embedded in the abnormal lung parenchyma; the adenocarcinoma cells have moderately pleomorphic nuclei with large nucleoli
• immunohistochemical analysis demonstrates that the tumors in these mice express the mutant human EGFR protein and that they are composed of cells that express surfactant protein C, characteristic of type II pneumocytes, but not Clara cell protein CC26
• discontinuation of doxycycline treatment in two mice after 43 and 55 days resulted in complete disappearance of lung opacities on MRI within a week; histologic examination at 32 and 169 days after deinduction revealed that the tumors had regressed completely, in one case leaving scar tissue
• treatment of tumor-bearing mice with the tyrosine kinase inhibitor erlotinib, while the mice continued receiving doxycycline, resulted in partial to complete disappearance of opacities on MRI in 2-8 days and, in mice examined after at least 4 days on erlotinib, complete or nearly complete (i.e., some residual tumor cells remained) histological regression of the tumors
• after only 4 days' induction with doxycycline, lung tissue from doubly transgenic mice contained nearly 2-fold the number of type II pneumocytes, identified by staining with antibody against surfactant protein C, than control tissue
• immunohistochemical analysis demonstrates that the tumors induced by doxycycline in these mice express the mutant human EGFR protein and that they are composed of cells that express surfactant protein C, characteristic of type II pneumocytes, but not Clara cell protein CC26

neoplasm
• as early as 2 weeks after initiation of doxycycline, lungs of bitransgenic mice exhibit scattered thickening of the alveolar walls due to proliferation of abnormal pneumocytes, with a lepidic growth pattern similar to human bronchioalveolar carcinoma (BAC), a subtype of lung adenocarcinoma; this wall thickening may be progressive, gradually compressing the air spaces
• after longer than 4 weeks on doxycycline, bitransgenic mice develop multifocal invasive adenocarcinoma of the lungs, with papilliform tumors of varying size embedded in the abnormal lung parenchyma; the adenocarcinoma cells have moderately pleomorphic nuclei with large nucleoli
• immunohistochemical analysis demonstrates that the tumors in these mice express the mutant human EGFR protein and that they are composed of cells that express surfactant protein C, characteristic of type II pneumocytes, but not Clara cell protein CC26
• discontinuation of doxycycline treatment in two mice after 43 and 55 days resulted in complete disappearance of lung opacities on MRI within a week; histologic examination at 32 and 169 days after deinduction revealed that the tumors had regressed completely, in one case leaving scar tissue
• treatment of tumor-bearing mice with the tyrosine kinase inhibitor erlotinib, while the mice continued receiving doxycycline, resulted in partial to complete disappearance of opacities on MRI in 2-8 days and, in mice examined after at least 4 days on erlotinib, complete or nearly complete (i.e., some residual tumor cells remained) histological regression of the tumors

Mouse Models of Human Disease
OMIM ID Ref(s)
Lung Cancer 211980 J:109092




Genotype
MGI:2652187
cx19
Allelic
Composition
Tg(tetO-Plau)1Ths/0
Tg(Scgb1a1-rtTA)1Jaw/0
Genetic
Background
involves: C57BL/6 * SJL
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Scgb1a1-rtTA)1Jaw mutation (3 available)
Tg(tetO-Plau)1Ths mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
mortality/aging
• mice exhibit decreased mortality rate following bleomycin-induced lung injury

homeostasis/metabolism
• mice exhibit decreased mortality rate following bleomycin-induced lung injury




Genotype
MGI:3693292
cx20
Allelic
Composition
Tg(Scgb1a1-rtTA)1Jaw/0
Tg(tetO/CMV-KRAS*G12C)9.1Msmi/0
Genetic
Background
involves: FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Scgb1a1-rtTA)1Jaw mutation (3 available)
Tg(tetO/CMV-KRAS*G12C)9.1Msmi mutation (1 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
respiratory system
• single adenoma was detected at 3 months; at 6, 9, and 12 months of treatment, incidence increases; mice develop higher incidence of proliferative changes with lower latency than SFTPC/KRAS mice
• at 12 months of treatment, 2 adenomas have progressed to low grade carcinomas
• after 12 days of doxycycline (DOX) treatement, small, hyperplastic lung foci are detected; untreated mice have normal lungs
• after 5 weeks of DOX treatment, extensive epithelial hyperplasia of alveolar region of lung is observed; untreated mice have normal lungs

neoplasm
• after 3 months treatment, visible macroscopic lesions are found; tumor incidence at 3 months is 55%, with multiplicity of 3.5 tumors/mouse
• lesions are <1mm in size
• early hyperplastic lesions are of bronchiolar origin
• at 6 and 9 months DOX treatment, visible lesions increase in number; multiplicity is 28.8 and 34 tumors/mouse after 9 and 12 months, higher than SFTPC/KRAS bitransgenic mice; treated monotransgenic mice show no tumor incidence
• when DOX treatment was stopped after 9 months, within 2 weeks only 4 tumors are visible on lung surface; these remain after 1 months; minimal hyperplastic foci microscopically are detectable, showing no proliferation (or apoptosis)
• single adenoma was detected at 3 months; at 6, 9, and 12 months of treatment, incidence increases; mice develop higher incidence of proliferative changes with lower latency than SFTPC/KRAS mice
• at 12 months of treatment, 2 adenomas have progressed to low grade carcinomas




Genotype
MGI:3586366
cx21
Allelic
Composition
Tg(tetO-Vegfa)90Ala/?
Tg(Scgb1a1-rtTA)1Jaw/?
Genetic
Background
involves: FVB/N
Find Mice Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Tg(Scgb1a1-rtTA)1Jaw mutation (3 available)
Tg(tetO-Vegfa)90Ala mutation (0 available)
phenotype observed in females
phenotype observed in males
N normal phenotype
respiratory system
• administration of doxycycline to pregnant mother and consequent VEGF-A164 expression in conducting airway epithelial cells of E10.5 to E16.5 embryo caused irregular evagination of epithelium into the lumen of bronchi and bronchioli





Contributing Projects:
Mouse Genome Database (MGD), Gene Expression Database (GXD), Mouse Tumor Biology (MTB), Gene Ontology (GO), MouseCyc
Citing These Resources
Funding Information
Warranty Disclaimer & Copyright Notice
Send questions and comments to User Support.
last database update
08/23/2016
MGI 6.05
The Jackson Laboratory